UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

☒   QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2016

 

☐   TRANSITION REPORT UNDER SECTION13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM __________ TO __________

 

COMMISSION FILE NUMBER: 000-54819

 

BIOSOLAR, INC.

(Name of registrant in its charter)

 

Nevada		20-4754291
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

27936 Lost Canyon Road, Suite 202 , Santa Clarita, CA 91387

(Address of principal executive offices) (Zip Code)

 

Issuer’s telephone Number: (661) 251-0001

 

Indicate by check mark whether the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ☒   No  ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  ☒   No  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

	Large accelerated filer ☐	Accelerated filer ☐
	Non-accelerated filer ☐	Smaller reporting company ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  ☐   No  ☒

 

The number of shares of registrant’s common stock outstanding, as of April 27, 2016 was 19,924,208.

 

 

 

BIOSOLAR, INC.

INDEX

 

PART I: FINANCIAL INFORMATION
ITEM 1:	FINANCIAL STATEMENTS (Unaudited)	1
	Condensed Balance Sheets	1
	Condensed Statements of Operations	2
	Condensed Statement of Shareholders' Deficit	3
	Condensed Statements of Cash Flows	4
	Notes to the Condensed Financial Statements	5
ITEM 2:	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	11
ITEM 3:	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	14
ITEM 4:	CONTROLS AND PROCEDURES	14
PART II: OTHER INFORMATION
ITEM 1	LEGAL PROCEEDINGS	15
ITEM 1A:	RISK FACTORS	15
ITEM 2	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	15
ITEM 3	DEFAULTS UPON SENIOR SECURITIES	15
ITEM 4	MINE SAFETY DISCLOSURES	15
ITEM 5	OTHER INFORMATION	15
ITEM 6:	EXHIBITS	16
SIGNATURES		17

 

 

PART I – FINANCIAL INFORMATION 

 

ITEM 1. FINANCIAL STATEMENTS

 

BIOSOLAR, INC.

CONDENSED BALANCE SHEETS

 

		March 31, 2016				December 31, 2015
		(Unaudited)
ASSETS
CURRENT ASSETS
Cash		$	230,167			$	202,610
Prepaid expenses			134,984				86,943
TOTAL CURRENT ASSETS			365,151				289,553
PROPERTY AND EQUIPMENT
Machinery and equipment			28,855				28,855
Less accumulated depreciation			(18,092	)			(17,326	)
NET PROPERTY AND EQUIPMENT			10,763				11,529
OTHER ASSETS
Patents			70,270				70,270
Deposit			770				770
TOTAL OTHER ASSETS			71,040				71,040
TOTAL ASSETS		$	446,954			$	372,122
LIABILITIES AND SHAREHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable		$	35,448			$	2,055
Accrued expenses			142,893				110,676
Derivative liability			7,654,202				7,878,599
Related party convertible promissory notes net of debt discount of $61,587 and $46,354, respectively			123,413				138,646
Convertible promissory notes net of debt discount of $157,094 and $232,645, respectively			1,281,106				966,855
TOTAL CURRENT LIABILITIES			9,237,062				9,096,831
SHAREHOLDERS' DEFICIT
Preferred stock, $0.0001 par value; 10,000,000 authorized common shares			-				-
Common stock, $0.0001 par value; 500,000,000 authorized common shares 19,457,498 and 17,995,953 shares issued and outstanding, respectively			1,945				1,799
Additional paid in capital			7,886,879				7,474,644
Accumulated deficit			(16,678,932	)			(16,201,152	)
TOTAL SHAREHOLDERS' DECIFIT			(8,790,108	)			(8,724,709	)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT		$	446,954			$	372,122

 

The accompanying notes are an integral part of these unaudited condensed financial statements

 

 

BIOSOLAR, INC.

CONDENSED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED MARCH 31, 2016 AND 2015

(Unaudited)

 

		Three Months Ended
		March 31, 2016				March 31, 2015
REVENUE		$	-			$	-
OPERATING EXPENSES
General and administrative expenses			525,126				118,146
Research and development			80,451				34,904
Depreciation and amortization			766				2,094
TOTAL OPERATING EXPENSES			606,343				155,144
LOSS FROM OPERATIONS BEFORE  OTHER INCOME			(606,343	)			(155,144	)
TOTAL OTHER INCOME/(EXPENSES)
Interest income			15				7
Gain on conversion of debt and change in derivative liability			304,112				485,233
Interest expense			(175,564	)			(85,443	)
TOTAL OTHER INCOME/(EXPENSES)			128,563				399,797
NET (LOSS) INCOME		$	(477,780	)		$	244,653
BASIC AND DILUTED (LOSS) INCOME PER SHARE		$	(0.03	)		$	0.02
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED			18,684,577				11,969,330

 

The accompanying notes are an integral part of these unaudited condensed financial statements

 

 

BIOSOLAR, INC.

CONDENSED STATEMENT OF SHAREHOLDERS' DEFICIT

FOR THE THREE MONTHS ENDED MARCH 31, 2016 AND 2015

 

																		Additional
		Preferred Stock								Common Stock								Paid-in				Accumulated
		Shares				Amount				Shares				Amount				Capital				Deficit				Total
Balance at December 31, 2015			-			$	-				17,995,953			$	1,799			$	7,474,644			$	(16,201,152	)		$	(8,724,709	)
Issuance of common shares for converted promissory notes and accrued interest			-				-				1,461,545				146				19,293				-				19,439
Stock based compensation			-				-				-				-				392,942				-				392,942
Net Loss for the three months ended March 31, 2016			-				-				-				-				-				(477,780	)			(477,780	)
Balance at March 31, 2016 (unaudited)			-			$	-				19,457,498			$	1,945			$	7,886,879			$	(16,678,932	)		$	(8,790,108	)

 

The accompanying notes are an integral part of these unaudited condensed financial statements

 

 

BIOSOLAR, INC.

CONDENSED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2016 AND 2015

(Unaudited)

 

		Three Months Ended
		March 31, 2016				March 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) Income		$	(477,780	)		$	244,653
Adjustment to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense			766				2,094
Stock based compensation			392,942				6,486
Loss on conversion of debt and change in derivative liability			(304,112	)			(485,233	)
Amortization of debt discount recognized as interest expense			140,033				66,972
Changes in Assets and Liabilities
(Increase) Decrease in:
Prepaid expenses			(48,041	)			(20,205	)
Increase (Decrease) in:
Accounts payable			33,393				14,420
Accrued expenses			35,356				18,202
NET CASH USED IN OPERATING ACTIVITIES			(227,443	)			(152,611	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment			-				(759	)
Patent expenditures			-				(4,732	)
NET CASH USED IN INVESTING ACTIVITIES			-				(5,491	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible promissory notes			255,000				185,000
NET CASH PROVIDED BY FINANCING ACTIVITIES			255,000				185,000
NET INCREASE IN CASH			27,557				26,898
CASH, BEGINNING OF PERIOD			202,610				146,640
CASH, END OF PERIOD		$	230,167			$	173,538
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid		$	176			$	270
Taxes paid		$	-			$	-
SUPPLEMENTAL SCHEDULE OF NON-CASH TRANSACTIONS
Common stock issued for convertible notes and accrued interest		$	19,439			$	11,939

 

The accompanying notes are an integral part of these unaudited condensed financial statements

 

 

BIOSOLAR, INC.

NOTES TO CONDENSED FINANICAL STATEMENTS – (UNAUDITED)

THREE MONTHS ENDED MARCH 31, 2016

 

1.	Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. For further information refer to the financial statements and footnotes thereto included in the Company's Form 10-K for the year ended December 31, 2015.

 

Going Concern

The accompanying financial statements have been prepared on a going concern basis of accounting, which contemplates continuity of operations, realization of assets and liabilities and commitments in the normal course of business. The accompanying financial statements do not reflect any adjustments that might result if the Company is unable to continue as a going concern. The Company has not generated significant revenue, and has negative cash flows from operations, which raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern and appropriateness of using the going concern basis is dependent upon, among other things, additional cash infusion. The Company has historically obtained funds through private placements offerings of equity and debt. Management believes that it will be able to continue to raise funds by sale of its securities to its existing shareholders and prospective new investors to provide the additional cash needed to meet the Company’s obligations as they become due, and will allow the development of its core of business. There is no assurance that the Company will be able to continue raising the required capital for its operations.

 

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

This summary of significant accounting policies of the Company are presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

 

Revenue Recognition

The Company will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable is reasonably assured. To date, the Company has not had significant revenues and is in the development stage.

 

Cash and Cash Equivalent

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, derivative liabilities and the fair value of stock options. Actual results could differ from those estimates.

 

Intangible Assets

Intangible assets consist of patents that are initially measured at the lower of cost or fair value.  The patents are deemed to have an indefinite life and are not amortized. The patents are assessed annually for impairment, or whenever conditions indicate the asset may be impaired, and any such impairment will be recognized in the period identified.

 

Stock-Based Compensation

The Company measures the cost of employee services received in exchange for an equity award based on the grant-date fair value of the award. All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee, consultant, or director are required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to employees and non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted is re-measured each period.

 

Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based payment and stock price volatility.  The Company uses the Black-Scholes option-pricing model to value its stock option awards which incorporate the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life. On March 24, 2015, the Company granted 2,450,000 stock options with an exercise price of $0.09 per share, and on September 2, 2015 the Company granted an additional 13,500,000 stock options with an exercise price of $0.26 per share. The options will vest 1/25 on a monthly basis starting April 24, 2015 and October 1, 2015, respectively, and terminate seven (7) years from the date of grant or upon termination of employment.

 

 

BIOSOLAR, INC.

NOTES TO CONDENSED FINANICAL STATEMENTS – (UNAUDITED)

THREE MONTHS ENDED MARCH 31, 2016

 

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Income (Loss) per Share Calculations

Loss per Share dictates the calculation of basic earnings per share and diluted earnings per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the three months ended March 31, 2016 and 2015, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. The Company has excluded 15,975,000 options, 245,000 warrants, and the shares issuable from convertible debt of $1,623,200 for the three months ended March 31, 2016.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments, requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of March 31, 2016, the amounts reported for cash, inventory, prepaid expenses, accounts payable, and accrued expenses, approximate the fair value because of their short maturities.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

	●	Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;
	●	Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
	●	Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows at March 31, 2016:

 

			Total				(Level 1)				(Level 2)				(Level 3)
	Derivative Liability		$	7,654,202			$	-			$	-			$	7,654,202
	Total liabilities measured at fair value		$	7,654,202			$	-			$	-			$	7,654,202

 

The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value:

 

	Beginning balance as of January 1, 2016		$	7,878,599
	Fair value of derivative liabilities issued			79,715
	Gain on conversion of debt and change in derivative liability			(304,112	)
	Ending balance as of March 31, 2016		$	7,654,202

 

Recently Issued Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements.

 

 

BIOSOLAR, INC.

NOTES TO CONDENSED FINANICAL STATEMENTS – (UNAUDITED)

THREE MONTHS ENDED MARCH 31, 2016

 

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Recently Issued Accounting Pronouncements (Continued)

In August 2014, FASB issued ASU 2014-15, “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this ASU provide that guidance. In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an Entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for public and nonpublic entities for annual periods ending after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2014-15 on the Company’s financial statements.

 

3.	CAPITAL STOCK

 

During the three months ended March 31, 2016, the Company issued 1,461,545 shares of common stock at a price of $0.0133 per share upon conversion of $16,300 in convertible promissory notes, including $3,139 in accrued interest.

 

4.	STOCK OPTIONS AND WARRANTS

 

During the three months ended March 31, 2016, the Company did not grant any stock options.

 

			March 31, 2016
							Weighted
			Number				average
			of				exercise
			Options				price
	Outstanding, January 1, 2016			15,978,333			$	0.23
	Granted			-				-
	Exercised			-				-
	Expired			(3,333	)		$	0.23
	Outstanding, March 31, 2016			15,975,000			$	0.23
	Exercisable at the end of period			4,441,000			$	0.22

 

The weighted average remaining contractual life of options outstanding as of March 31, 2016 was as follows:

 

											Weighted
											Average
			Stock				Stock				Remaining
	Exercisable		Options				Options				Contractual
	Prices		Outstanding				Exercisable				Life (years)
	0.40			25,000				25,000			1.92
	0.09			2,450,000				1,176,000			5.98
	0.26			13,500,000				3,240,000			6.43
	Total			15,975,000				4,441,000

 

The stock-based compensation expense recognized in the statement of operations during the three months ended March 31, 2016 related to the granting of these options was $392,942.

 

As of March 31, 2016, there was no intrinsic value with regards to the outstanding options.

 

 

BIOSOLAR, INC.

NOTES TO CONDENSED FINANICAL STATEMENTS – (UNAUDITED)

THREE MONTHS ENDED MARCH 31, 2016

 

4.	STOCK OPTIONS AND WARRANTS (Continued)

 

Warrants

During the three months ended March 31, 2016, the Company granted no warrants. As of March 31, 2016, 245,000 warrants are outstanding. The warrant terms are 5 years with 95,000 warrants expiring in October 2016 and 150,000 warrants expiring in October 2017.

 

			March 31, 2016
							Weighted
			Number				average
			of				exercise
			Warrants				price
	Outstanding, January 1, 2016			245,000			$	0.97
	Granted			-				-
	Exercised			-				-
	Expired			-				-
	Outstanding, March 31, 2016			245,000			$	0.97
	Exercisable at the end of period			245,000			$	0.97

 

5.	CONVERTIBLE PROMISSORY NOTES

 

On January 18, 2013, the Company entered into a securities purchase agreement for the sale of 10% convertible promissory note in the aggregate principal amount of up to $80,000, to be advanced in amounts at the lender’s discretion. Upon execution of the securities purchase agreement, the Company received an advance of $10,000. On April 16, 2013, the Company received an additional advance of $25,000. The total advances received were $35,000, of which principal in the amount of $25,000, and $2,886 in accrued interest was converted into 183,481 shares of common stock at fair value of $0.43 and $0.367 per share on September 29, 2013 and October 3, 2014. On July 6, 2015 the Company issued 735,153 shares of common stock at a fair value of $0.0133 upon conversion of principal in the amount of $8,000, plus accrued interest of $1,778, leaving a balance of $2,000. During the month of July 2013, the Company extended the maturity date of the note from six (6) months to eighteen (18) months from the effective date of each advance. The note was fully converted on January 26, 2016, at which time the Company issued 1,461,545 shares of common stock.

 

On May 2, 2014, the Company entered into a securities purchase agreement, providing for the sale by the Company of 10% unsecured convertible note in the aggregate principal amount of up to $500,000, to be advanced in amounts at the lender’s discretion. Upon execution of the securities purchase agreement, the Company received an advance in the amount of $50,000. On various dates, the Company received additional advances in the aggregate sum of $450,000, for a total aggregate sum of $500,000. As of December 31, 2015, the remaining principal balance was $467,500. During the three months ended March 31, 2016, the Company issued 1,269,353 shares of common stock for principal in the amount of $14,300, plus accrued interest of $2,582, leaving a principal balance of $453,200. Each advance matures eighteen (18) months from the effective date of each advance, which was extended to sixty (60) months on January 12, 2016. The note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.25 per share of common stock, b) fifty percent (50%) of the average three (3) lowest trading prices of three (3) separate trading days recorded after the effective date, or c) the lowest effective price granted to any person or entity after the effective date to acquire common stock. The fair value of the note has been determined by using the Black-Scholes pricing model with an expected life of sixty (60) months. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $17,334 during the three months ended March 31, 2016.

 

On January 30, 2015, the Company entered into a securities purchase agreement, providing for the sale by the Company of 10% unsecured convertible note in the aggregate principal amount of up to $500,000, to be advanced in amounts at the lender’s discretion. Upon execution of the securities purchase agreement, the Company received an advance in the amount of $50,000. On various dates, the Company received additional advances in the aggregate sum of $450,000. The principal balance at March 31, 2016 was $500,000. Each advance matures eighteen (18) months from the effective date of each advance, which was extended to sixty (60) months on January 12, 2016. The note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.15 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded since the original effective date of the note, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. The fair value of the note has been determined by using the Black-Scholes pricing model with an expected life of sixty (60) months. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $70,880 during the three months ended March 31, 2016.

 

 

BIOSOLAR, INC.

NOTES TO CONDENSED FINANICAL STATEMENTS – (UNAUDITED)

THREE MONTHS ENDED MARCH 31, 2016

 

5.	CONVERTIBLE PROMISSORY NOTES (Continued)

 

On October 1, 2015, the Company entered into a securities purchase agreement, providing for the sale by the Company of 10% unsecured convertible notes in the aggregate principal amount of up to $500,000, to be advanced in amounts at the lender’s discretion. Upon execution of the securities purchase agreement, the Company received an advance in the amount of $90,000. On various dates, the Company received additional advances in the aggregate sum of $395,000. The principal balance at March 31, 2016 was $485,000. Each advance matures twelve (12) months from the effective date of each advance. The note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.25 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded since the original effective date of the note, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. The fair value of the note has been determined by using the Black-Scholes pricing model with an expected life of twelve (12) months. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $39,870 during the year ended December 31, 2015.

 

RELATED PARTY CONVERTIBLE PROMISSORY NOTES

On June 5, 2013, the Company issued two 5% convertible promissory notes in exchange for services rendered by the Company’s Chief Executive Officer ($114,000) and Chief Technology Officer ($128,000) in the aggregate amount of $242,000. On March 5, 2014, the Company issued 694,191 upon partial conversion of principal in the amount of $55,000, plus accrued interest of $2,063, leaving a remaining balance of $187,000. On April 17, 2015, the Company issued 2,187,692 shares of common stock upon conversion of $130,000 in principal, plus $12,200 in accrued interest, leaving a balance of $57,000. The notes are convertible into shares of common stock of the Company at a conversion price equal to the lesser of $0.24 per share or the closing price per share of common stock recorded on the trading day immediately preceding the date of conversion. The notes matured two (2) years from their effective dates, and were extended on June 22, 2015 for one (1) year with a maturity date of June 5, 2016. The fair value of the notes has been determined by using the Black-Scholes pricing model with an expected life of two (2) years.

 

On December 18, 2014, the Company issued two 5% convertible promissory notes in exchange for services rendered by the Company’s Chief Executive Officer ($68,000) and Chief Technology Officer ($61,000) in the aggregate amount of $128,000. The notes are convertible into shares of common stock of the Company at a conversion price equal to the lesser of $0.101 per share of common stock or the closing price per share of common stock recorded on the trading day immediately preceding the date of conversion. The notes mature two (2) years from their effective dates. The fair value of the notes has been determined by using the Black-Scholes pricing model with an expected life of two (2) years. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $11,949 during the three months ended March 31, 2016.

 

We evaluated the financing transactions in accordance with ASC Topic 815, Derivatives and Hedging, and determined that the conversion feature of the convertible promissory note was not afforded the exemption for conventional convertible instruments due to its variable conversion rate. The note has no explicit limit on the number of shares issuable so they did not meet the conditions set forth in current accounting standards for equity classification. The Company elected to recognize the note under paragraph 815-15-25-4, whereby, there would be a separation into a host contract and derivative instrument. The Company elected to initially and subsequently measure the note in its entirety at fair value, with changes in fair value recognized in earnings. The Company recorded a derivative liability representing the imputed interest associated with the embedded derivative. The derivative liability is adjusted periodically according to the stock price fluctuations.

 

6.	DERIVATIVE LIABILITIES

 

The convertible notes issued and described in Note 5 do not have fixed settlement provisions because their conversion prices are not fixed. The conversion feature has been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations.

 

During the three months ended March 31, 2016, as a result of the convertible notes (“Notes”) issued that were accounted for as derivative liabilities, we determined that the fair value of the conversion feature of the convertible notes at issuance was $79,715, based upon a Black-Sholes-Model calculation. We recorded the full value of the derivative as a liability at issuance with an offset to valuation discount, which will be amortized over the life of the Notes.

 

During the three months ended March 31, 2016, approximately $16,300 convertible notes were converted. As a result of the conversion of these notes and the change in fair value of the remaining notes, the Company recorded a gain on conversion of debt and change in derivative of $304,112 in the statement of operations for the three months ended March 31, 2016. At March 31, 2016, the fair value of the derivative liability was $7,654,202.

 

 

BIOSOLAR, INC.

NOTES TO CONDENSED FINANICAL STATEMENTS – (UNAUDITED)

THREE MONTHS ENDED MARCH 31, 2016

 

6.	DERIVATIVE LIABILITIES (Continued)

 

For purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:

 

			3/31/2016
	Risk free interest rate		0.52% - 1.21%
	Stock volatility factor		126.74% - 184.98%
	Weighted average expected option life		1 year - 5 years
	Expected dividend yield		None

 

7.	SUBSEQUENT EVENT

 

Management has evaluated subsequent events according to the requirements of ASC TOPIC 855 and has determined that there are the following subsequent events:

 

On April 8, 2016, the Company issued 466,710 shares of common stock upon conversion of $5,200 in principal, plus accrued interest of $1,007. The securities purchase agreement was entered into on May 2, 2014, providing for the sale by the Company of 10% unsecured convertible note in the aggregate principal amount of $500,000, to be advanced in amounts at the lender’s discretion. The note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.25 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded on any trade day after the effective date or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock.

  

 

ITEM 2:  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Special Note on Forward-Looking Statements.

 

Certain statements in “Management’s Discussion and Analysis or Plan of Operation” below, and elsewhere in this quarterly report, are not related to historical results, and are forward-looking statements. Forward-looking statements present our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements frequently are accompanied by such words such as “may,” “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” or the negative of such terms or other words and terms of similar meaning. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, achievements, or timeliness of such results. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such forward-looking statements. We are under no duty to update any of the forward-looking statements after the date of this quarterly report. Subsequent written and oral forward looking statements attributable to us or to persons acting in our behalf are expressly qualified in their entirety by the cautionary statements and risk factors set forth in our annual report on Form 10-K filed with the SEC on March 4, 2016, and in other reports filed by us with the SEC.

 

 You should read the following description of our financial condition and results of operations in conjunction with the financial statements and accompanying notes included in this report.

 

Overview

 

We are developing innovative technologies to reduce the cost per watt of electricity produced by Photovoltaic solar modules. The process for producing electricity from sunlight is known as Photovoltaics. Photovoltaics ("PV") is the science of capturing and converting sun light into electricity.

 

We are currently focusing on developing a low cost energy storage solution based on our polymer-based supercapacitor technology that we believe will result in higher energy capacity, lower cost per watt, and substantially longer life of energy storage devices.

 

We were incorporated in the State of Nevada on April 24, 2006, as BioSolar Labs, Inc. Our name was changed to BioSolar, Inc. on June 8, 2006. Our principal executive offices are located at 27936 Lost Canyon Road, Suite 202, Santa Clarita, California 91387, and our telephone number is (661) 251-0001. Our fiscal year end is December 31.

 

Recent Transactions

 

On January 21, 2016, the Company signed an agreement to extend the funding of its sponsored research program with the University of California, Santa Barbara.

 

Application of Critical Accounting Policies

 

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to impairment of property, plant and equipment, intangible assets, deferred tax assets and fair value computation using the Black Scholes option pricing model. We base our estimates on historical experience and on various other assumptions, such as the trading value of our common stock and estimated future undiscounted cash flows, that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions; however, we believe that our estimates, including those for the above-described items, are reasonable.

 

Use of Estimates

 

In accordance with accounting principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions relate to recording net revenue, collectability of accounts receivable, useful lives and impairment of tangible and intangible assets, accruals, income taxes, inventory realization, stock-based compensation expense and other factors. Management believes it has exercised reasonable judgment in deriving these estimates. Consequently, a change in conditions could affect these estimates.

 

 

Fair Value of Financial Instruments

 

Our cash, cash equivalents, investments, inventory, prepaid expenses, and accounts payable are stated at cost which approximates fair value due to the short-term nature of these instruments.

 

Recently Issued Accounting Pronouncements

 

In August 2014, FASB issued ASU 2014-15, “Presentation of Financial Statements Going Concern (Subtopic 205-40) –  Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern ”. Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this ASU provide that guidance. In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term  substantial doubt,  (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for public and nonpublic entities for annual periods ending after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2014-15 on the Company’s financial statements.

 

Management reviewed currently issued pronouncements during the three months ended March 31, 2016, and does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements.

 

Results of Operations – Three Months Ended March 31, 2016 Compared to the Three Months Ended March 31, 2015

 

OPERATING EXPENSES

 

General and Administrative Expenses

 

General and administrative (“G&A”) expenses increased by $406,980 to $525,126 for the three months ended March 31, 2015, compared to $118,146 for the prior period March 31, 2015. This increase in G&A expenses was the result of an increase in non-cash stock compensation expense of $386,456, an increase in marketing expense of $9,620, and an increase in professional fees of $6,239, with an overall increase of $4,665 in G&A expenses.

 

Research and Development

 

Research and Development (“R&D”) expenses increased by $45,547 to $80,451 for the three months ended March 31, 2016, compared to $34,904 for the prior period ended March 31, 2015. This overall increase in R&D expenses was the result of developing technologies and materials for storing electrical energy produced by photovoltaic solar modules.

 

Other Income/(Expenses)

 

Other income and (expenses) decreased by $271,234 to $128,563 for the three months ended March 31, 2016, compared to $399,797 for the prior period ended March 31, 2015. The decrease was the result of a decrease in non-cash gain on change in fair value of the derivative instruments of $181,120, with an increase in interest expense in the amount of $90,122, which includes non-cash expense of amortization of debt discount in the amount of $73,061, and an increase in interest income of $8. The decrease in other income and (expenses) was primarily due to the net change in the fair value of the derivative instruments.

 

Net Income (Loss)

 

Our net loss $(477,780) for the three months ended March 31, 2016, compared to net income of $244,653 for the prior period ended March 31, 2015. The increase in net loss was due to a decrease in non-cash other income (expenses) associated with the net change in derivative instruments, and an overall increase in operating expenses primarily associated with non-cash stock compensation.  The Company has not generated any revenues.

 

 

LIQUIDITY AND CAPITAL RESOURCES

 

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures.

 

The condensed financial statements have been prepared on a going concern basis of accounting, which contemplates continuity of operations, realization of assets and liabilities and commitments in the normal course of business. The accompanying condensed financial statements do not reflect any adjustments that might result if we are unable to continue as a going concern. During the three months ended March 31, 2016, we did not generate any revenues, incurred a net loss of $477,780 and cash used in operations of $227,443. As of March 31, 2016, we had a working capital deficiency of $8,871,911 and a shareholders’ deficit of $8,790,108. These factors, among others raise substantial doubt about our ability to continue as a going concern. Our independent auditors, in their report on our audited financial statements for the year ended December 31, 2015 expressed substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern and suitability of using the going concern basis is dependent upon, among other things, additional cash infusion. In the three months ended March 31, 2016 we obtained funding through the sale of our securities. Management believes that we will be able to continue to raise funds through the sale of our securities to existing and new investors. Management believes that funding from existing and prospective new investors, and future revenue will provide the additional cash needed to meet our obligations as they become due, and will allow the development of our core business operations.

 

As of March 31, 2016, we had a working capital deficit of $8,871,911 compared to working capital deficit of $8,807,278 for the year ended December 31, 2015. This increase in capital deficit of $64,633 was due primarily to an increase in cash, prepaid expenses, accounts payable, accrued expenses, the issuance of convertible promissory notes, and a decrease in derivative liability associated with the notes.

 

During the three months ended March 31, 2016, we used $227,443 of cash for operating activities, as compared to $152,611 for the prior period ended March 31, 2015. The increase in the use of cash for operating activities was a result of an increase in net loss, which included an increase in research and development expenses of $45,547 compared to the prior three months ended March 31, 2015.

 

Cash used in investing activities for the three months ended March 31, 2016 and 2015, were $0 and $5,491, respectively. The overall net change in investing activities was primarily due to the purchase of small office equipment and patent expenditures in the prior period.

 

Cash provided from financing activities was $255,000 for the three months ended March 31, 2016, as compared to $185,000 for the prior period ended March 31, 2015. Our ability to continue as a going concern is dependent upon raising capital from financing transactions and future revenue. Our capital needs have primarily been met from the proceeds of private placements, as we currently have not generated any revenues.

 

We have a material commitment for capital expenditures in the form of a sponsored research agreement with the University of California Santa Barbara during the next twelve months.  Although proceeds from our financing activities are currently sufficient to fund our operating expenses through the next four months, we will need to raise additional funds in the future so that we can expand our operations. Therefore, our future operations are dependent on our ability to secure additional financing.  Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. However, the trading price of our common stock and a downturn in the U.S. equity and debt markets could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, or experience unexpected cash requirements that would force us to seek additional financing. Furthermore, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. The inability to obtain additional capital may restrict our ability to grow and may reduce our ability to continue to conduct business operations. If we are unable to obtain additional financing, we may have to curtail our marketing and development plans and possibly cease our operations.

 

We believe that we have assets to ensure that we can continue to operate without liquidation over the next four months, due to our cash on hand, and our ability in the past to raise money from our investor base.  Based on the aforesaid, we believe we have the ability to continue our operations for the next twelve months and will be able to realize assets and discharge liabilities in the normal course of our operations.

 

Our financial statements as of March 31, 2016 have been prepared under the assumption that we will continue as a going concern. Our independent registered public accounting firm has issued their report dated March 4, 2016 that included an explanatory paragraph expressing substantial doubt in our ability to continue as a going concern without additional capital becoming available. Our ability to continue as a going concern ultimately is dependent upon our ability to generate revenue, which is dependent upon our ability to obtain additional equity or debt financing, attain further operating efficiencies and, ultimately, to achieve profitable operations. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

 

PLAN OF OPERATION AND FINANCING NEEDS

 

We are engaged in the development of innovative technologies that will reduce the cost per watt of electricity generated by Photovoltaic solar modules.  We have developed BioBacksheet^R , our first commercial product, and we are currently focusing on developing a low cost energy storage technology and materials for supercapacitors and batteries by 2017.

 

Our plan of operation within the next six months is to utilize our cash balances to develop our polymer-based cathode technology for high capacity and low cost Lithium-ion batteries.  We believe that our current cash and investment balances will be sufficient to support development activity and general and administrative expenses for the next five months. Management estimates that it will require additional cash resources during 2016, based upon its current operating plan and condition. We expect increased expenses during the second half of 2016 as we ramp up prototyping efforts for Lithium-ion batteries incorporating our polymer-based cathode material.  We will be investigating additional financing alternatives, including equity and/or debt financing. There is no assurance that capital in any form would be available to us, and if available, on terms and conditions that are acceptable. If we are unable to obtain sufficient funds during the next fifteen months, we may be forced to reduce the size of our organization, which could have a material adverse impact on, or cause us to curtail and/or cease the development of our products.

 

Off-Balance Sheet Arrangements

 

We do not have any off balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues, result of operations, liquidity or capital expenditures.

  

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

  

n/a

  

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (i) recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms, and (ii) accumulated and communicated to our management, including our chief executive officer and chief financial officer, or person performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Changes in Internal Control Over Financial Reporting

 

There was no change to our internal control over financial reporting that occurred during our third fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

  

 

PART II - OTHER INFORMATION

  

ITEM 1. LEGAL PROCEEDINGS

 

We are not a party to any pending legal proceeding, nor is our property the subject of a pending legal proceeding, that is not in the ordinary course of business or otherwise material to the financial condition of our business. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

 

ITEM 1A. RISK FACTORS

 

There are no material changes from the risk factors previously disclosed in the Registrant’s Form 10-K filed on March 4, 2016.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

During the three months ended March 31, 2016, the Company issued 1,461,545 shares of common stock at a price per share of $0.0133 upon conversion of $16,300 in convertible promissory notes, plus $3,139 in accrued interest.

 

The Company relied on an exemption pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, in connection with the foregoing issuance.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable

 

ITEM 5. OTHER INFORMATION

 

None

 

 

 

ITEM 6. EXHIBITS

 

Exhibit No.		Description
31.1		Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to Sarbanes-Oxley Section 302 (filed herewith).
32.2		Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to 18 U.S.C. Section 1350 (filed herewith).

 

EX-101.INS		XBRL Instance Document
EX-101.SCH		XBRL Taxonomy Extension Schema Document
EX-101.CAL		XBRL Taxonomy Extension Calculation Linkbase
EX-101.DEF		XBRL Taxonomy Extension Definition Linkbase
EX-101.LAB		XBRL Taxonomy Extension Labels Linkbase
EX-101.PRE		XBRL Taxonomy Extension Presentation Linkbase

 

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California, on May 11, 2016.

 

	BIOSOLAR, INC.
	By:	/s/ David Lee
		Chief Executive Officer (Principal Executive Officer) and Acting Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

 

 

17